Increase in curative treatment and survival of lung cancer in Norway 2001–2016

Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Grimsrud, Tom Kristian; Haram, Per Magnus; Helbekkmo, Nina; Helland, Åslaug; Hjelde, Harald; Jakobsen, Bjørn; Møller, Bjørn; Petersen, M.T.; Strand, Trond Eirik; Wahl, Sissel Gyrid Freim; Aanerud, Marianne; Fjellbirkeland, Lars

doi:10.1007/s10654-019-00536-z

Cited by 14 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A strength of this study is the completeness of the registrations of national data in the CRN [6]. Also, in spite of the low concordance in staging, a high proportion of the patients has been given treatment with curative intention [6], and the 5 year relative survival for all diagnosed with lung cancer is high and has increased from 9.4% in 2001 [10] to 25.9% in 2019 [5] and 27.2% in 2020 [6].…”

Section: Discussionmentioning

confidence: 99%

Concordance between clinical and pathology TNM-staging in lung cancer

Solberg

Nilssen²,

Brustugun³

et al. 2022

Lung Cancer

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Concordance between clinical and pathology TNM-staging in lung cancer

Solberg

Nilssen²,

Brustugun³

et al. 2022

Lung Cancer

Self Cite

View full text Add to dashboard Cite

“…Screening with low dose computed tomography (LDCT) has proven to be beneficial in reducing the mortality related to lung cancer, which is mainly based on early detection of cancer and timely initiation of treatment ( 17 ). Third, the treatment of lung cancer has improved and 20–30% of patients are eligible for curing with surgery ( 18 ). In addition to surgery, other therapies have also been developed for patients with primary or metastatic lung cancer recently, including radiation therapy, thoracoscopic segmentectomy and thermal ablation therapy.…”

Section: Discussionmentioning

confidence: 99%

Using Population-Based Cancer Registration Data and Period Analysis to Accurately Assess and Predict 5-Year Relative Survival for Lung Cancer Patients in Eastern China

Zhang

Cheng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe assessment of long-term survival of lung cancer patients based on data from population-based caner registries, using period analysis, was scarce in China. We aimed to accurately assess the long-term survival of lung cancer patients, and to predict the long-term survival in the future, using cancer registry data from Taizhou City, eastern China.MethodsFour cancer registries with high-quality data were selected. Patients diagnosed with lung cancer during 2004–2018 were included. The long-term survival was evaluated using period analysis, with further stratification by sex, age at diagnosis and region. Additionally, projected 5-year relative survival (RS) of lung cancer patients for 2019-2023 was evaluated, using model-based period analysis.ResultsThe 5-year RS of lung cancer patients diagnosed during 2014–2018 was 40.2% (31.5% for men and 56.2% for women). A moderate age gradient was observed for the period estimate, with the estimate decreasing from 50.5 to 26.5% in the age group of 15–44 years and ≥75 years, respectively. The 5-year RS of urban area was higher than that of rural area (52.3% vs. 38.9%). The overall projected 5-year RS of lung cancer patients was 52.7% for 2019–2023, with estimate of 43.0 and 73.2% for men and women, respectively. A moderate age gradient was also observed for the projected estimate. Moreover, estimate reached nearly 50% for rural and urban areas.ConclusionPeriod analysis tended to provide the up-to-date and precise survival estimates for lung cancer patients, which is worth further application, and provides important evidence for prevention and intervention of lung cancer.

show abstract

“…This increase is also the most possible explanation for the slight reduction observed in the proportion of colorectal cancers receiving surgery, since patients with pRT and surgery were grouped as radiotherapy. For lung cancer there was a rapid increase in the proportion of patients receiving curative treatment (surgery, stereotactic radiotherapy and curatively fractionated radiotherapy) after 2010 23 . Despite this increase in the proportion of curatively treated patients, the waiting time for radiotherapy was reduced by over two weeks.…”

Section: Discussionmentioning

confidence: 99%

Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway

Nilssen

Brustugun

Eriksen

et al. 2019

Cancer Epidemiology

Self Cite

View full text Add to dashboard Cite

Background: In 2015, Norway implemented cancer patient pathways to reduce waiting times for treatment. The aims of this paper were to describe patterns in waiting time and their association with patient characteristics for colorectal, lung, breast and prostate cancers. Methods: National, population-based data from 2007-2016 were used. A multivariable quantile regression examined the association between treatment period, age, stage, sex, place of residence, and median waiting times. Results: Reduction in median waiting times for radiotherapy among colorectal, lung and prostate cancer patients ranged from 14-50 days. Median waiting time for surgery remained approximately 21 days for both colorectal and breast cancers, while it decreased by 7 and 36 days for lung and prostate cancers, respectively. The proportion of lung and prostate cancer patients with metastatic disease at the time of diagnosis decreased, while the proportion of colorectal patients with localised disease and patients with stage I breast cancer increased (p<0.001). After adjusting for case-mix, a patient's place of residence was significantly associated with waiting time for treatment (p<0.001), however, differences in waiting time to treatment decreased over the study period. Conclusions: Between 2007 and 2016, Norway experienced improved stage distributions and consistently decreasing waiting times for treatment. While these improvements occurred gradually, no significant change was observed from the time of cancer patient pathway implementation.

show abstract

Increase in curative treatment and survival of lung cancer in Norway 2001–2016

Cited by 14 publications

References 6 publications

Concordance between clinical and pathology TNM-staging in lung cancer

Concordance between clinical and pathology TNM-staging in lung cancer

Using Population-Based Cancer Registration Data and Period Analysis to Accurately Assess and Predict 5-Year Relative Survival for Lung Cancer Patients in Eastern China

Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway

Contact Info

Product

Resources

About